Proteome Sciences (LON:PRM) Shares Down 18.5% – Should You Sell?

Proteome Sciences plc (LON:PRM)’s share price was down 18.5% on Thursday . The stock traded as low as GBX 2.89 ($0.04) and last traded at GBX 2.89 ($0.04). Approximately 1,014,536 shares traded hands during mid-day trading, an increase of 367% from the average daily volume of 217,283 shares. The stock had previously closed at GBX 3.55 ($0.05).

Proteome Sciences Trading Up 12.3 %

The business’s 50-day simple moving average is GBX 4.05 and its 200-day simple moving average is GBX 3.46. The company has a market cap of £9.98 million, a PE ratio of -2.45 and a beta of 0.07. The company has a current ratio of 0.20, a quick ratio of 0.37 and a debt-to-equity ratio of -258.66.

Proteome Sciences (LON:PRM) last announced its quarterly earnings data on Thursday, April 10th. The company reported GBX (1.15) (($0.02)) earnings per share (EPS) for the quarter. Proteome Sciences had a negative return on equity of 0.01% and a negative net margin of 0.04%.

Proteome Sciences Company Profile

Proteome Sciences plc provides contract research services for the identification, validation, and application of protein biomarkers in the United States, the United Kingdom, European Union, and internationally. The company offers TMT LC-MS2, a standard method for analyzing cells and tissues when no phosphopeptide enrichment is required; TMT LC-MS3, a standard method for biomarker discovery in plasma and other samples where quantitative accuracy is a factor; SysQuant, provides an analysis of protein activity across regulatory and signaling pathways; and TMTcalibrator, analyzes where diseased or treated tissue can be analyzed in parallel with peripheral fluids.